Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01833 PA GOODDOCTOR
RTNominal down97.550 -2.350 (-2.352%)
Research Report

28/01/2021 18:01

{I-bank focus}HSBC cuts PA Good Doctor (01833) to HK$115

[ET Net News Agency, 28 January 2021] HSBC Global Research cut its target price for PA
Good Doctor (PAGD) (01833) to HK$115 from HK$139 and maintained its "buy" rating.
After raising money last year, PAGD's management shared its revised investment plans in
an attempt to drive better long-term growth. Key initiatives include: (1) Strengthening
its team of doctors; (2) Expanding its internet hospital footprint; and (3) Widening and
deepening its customer base.
The research house said these new initiatives require an initial investment that will
have a negative impact on PAGD's breakeven timeline, pushing it out to FY2024 from FY2022
by HSBC's estimation.
Factoring in the increased spending, which should peak in 1H 2022, HSBC expects PAGD's
operating loss to widen to RMB1.1bn in FY2021 and RMB976m in FY2022. (KL)

Remark: Real time quote last updated: 12/04/2021 12:31
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.